↓ Skip to main content

Dove Medical Press

Article Metrics

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

Overview of attention for article published in Neuropsychiatric Disease and Treatment, May 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
41 Mendeley
Title
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
Published in
Neuropsychiatric Disease and Treatment, May 2015
DOI 10.2147/ndt.s79347
Pubmed ID
Authors

Ernie Anand, Lovisa Berggren, Claudia Deix, Ágoston Tóth, David McDonnell

Abstract

To assess the long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of schizophrenia, focusing on clinical trial data consistent with the approved indication and dosing recommendations in the European label and which forms the basis for treatment decisions made by clinicians in daily clinical practice. This was a post hoc analysis of a 6-year open-label study of olanzapine LAI in patients (male or female, 18-75 years old) with schizophrenia entering this study following feeder studies of olanzapine LAI. Patients were flexibly dosed (45-405 mg, 2- to 4-week intervals), but those receiving oral olanzapine supplementation whose total olanzapine dose was >20 mg/day equivalent were excluded from this post hoc analysis. Data from 669 patients were analyzed (44.5% completed). Positive and Negative Syndrome Scale total scores did not change significantly from baseline to endpoint; Clinical Global Impression-Severity scores improved significantly. Mean weight change was +2.19 kg (P<0.001), with 40.8% of patients experiencing ≥7% weight gain. There were 24 occurrences of post-injection delirium/sedation syndrome (PDSS). Olanzapine LAI appeared to be effective in the long-term maintenance of schizophrenia, and the safety profile was consistent with that of oral olanzapine, except for injection-related events and PDSS events.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 15%
Other 6 15%
Student > Doctoral Student 6 15%
Student > Master 6 15%
Researcher 4 10%
Other 9 22%
Unknown 4 10%
Readers by discipline Count As %
Medicine and Dentistry 15 37%
Pharmacology, Toxicology and Pharmaceutical Science 5 12%
Psychology 4 10%
Nursing and Health Professions 3 7%
Neuroscience 3 7%
Other 5 12%
Unknown 6 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2015.
All research outputs
#7,844,410
of 14,535,828 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,002
of 2,442 outputs
Outputs of similar age
#94,613
of 235,581 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#26
of 52 outputs
Altmetric has tracked 14,535,828 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,581 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.